Do ditans and gepants have a place in acute migraine treatment?

Abstract

A systematic review and meta-analysis by Yang and colleagues, published in JAMA Open Network in October 2021, found that 5-HT1F receptor agonists or “ditans” (lasmiditan) and calcitonin gene-related peptide antagonists or “gepants” (rimegepant and ubrogepant) were not as effective in reducing pain 2 hours post-dose as compared to triptans. However, the study findings concluded gepants were less likely to cause mild to moderate adverse events compared to triptans.